Barings Corporate Investors MCI 深 沪
等待开盘 12-16 09:30:00 美东时间
20.11
-0.330
-1.61%
华盛通- 最 高20.48
- 今 开20.48
- 成交量 3.84万股
- 最 低 19.75
- 昨 收 20.44
- 总市值 4.11亿
- 52周最高 24.04
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 17.40
- 委 比 0.00%
- 总股本 2044.46万
- 历史最高 24.04
- 量 比 2.41
- 振 幅 3.57%
- 历史最低 0.335
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Barings Corporate Announces Q3 Preliminary Net Investment Income Of $7.077M Or $0.35/Shr
The Board of Trustees of Barings Corporate Investors (NYSE:MCI) (the "Trust") met on November 13, 2025, and would like to report its preliminary financial results for the third quarter of 2025.During the three months
11-14 04:37
Quest Diagnostics' New Blood Tests Accurately Detect Alzheimer's, Study Finds
Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology®
10-27 19:47
Health Canada Grants Authorization for Leqembi® (lecanemab)
STOCKHOLM, Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (...
10-27 10:56
Science Applications International Appoints James Reagan As Interim CEO
Science Applications International Corporation (NASDAQ:SAIC), a premier Fortune 500® company driving our nation's digital transformation across the defense, space, civilian, and intelligence markets, today announced
10-24 04:17
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanem...
10-14 13:14
Barings Corporate Investors declares $0.40 dividend
Barings Corporate Investors (NYSE:MCI) declares $0.40/share quarterly dividend, in line with previous. Forward yield 7.96% Payable Nov. 14; for shareholders of record Nov. 3; ex-div Nov. 3. See MCI Di...
10-10 03:43
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iq...
10-07 06:02
Eisai And Biogen Announce Lecanemab-Irmb Subcutaneous Injection Is Now Available In US As Maintenance Dosing Regimen For AD Treatment
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection
10-07 04:34
Eisai And Biogen's LEQEMBI Approved By Australia's TGA For Early Alzheimer's In ApoEε4 Non-Carriers And Heterozygotes
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"))) announced today that the
09-24 19:34
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab...
09-24 14:56
公司简介
公司名称
|
Barings Corporate Investors
|
行业分类
|
--
|
业务描述
|
Barings Corporate Investors, a closed-end investment company traded on the New York Stock Exchange, invests in small and middle market companies. The fund provides financing in the form of mezzanine debt and equity for acquisition transactions. Its principal investments are privately placed, below-investment grade, long term debt obligations with equity features such as common stock, warrants, conversion rights, or other equity features and, occasionally, preferred stocks.
|
Barings Corporate Announces Q3 Preliminary Net Investment Income Of $7.077M Or $0.35/Shr
The Board of Trustees of Barings Corporate Investors (NYSE:MCI) (the "Trust") met on November 13, 2025, and would like to report its preliminary financial results for the third quarter of 2025.During the three months
11-14 04:37
Quest Diagnostics' New Blood Tests Accurately Detect Alzheimer's, Study Finds
Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology®
10-27 19:47
Health Canada Grants Authorization for Leqembi® (lecanemab)
STOCKHOLM, Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (...
10-27 10:56
Science Applications International Appoints James Reagan As Interim CEO
Science Applications International Corporation (NASDAQ:SAIC), a premier Fortune 500® company driving our nation's digital transformation across the defense, space, civilian, and intelligence markets, today announced
10-24 04:17
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanem...
10-14 13:14
Barings Corporate Investors declares $0.40 dividend
Barings Corporate Investors (NYSE:MCI) declares $0.40/share quarterly dividend, in line with previous. Forward yield 7.96% Payable Nov. 14; for shareholders of record Nov. 3; ex-div Nov. 3. See MCI Di...
10-10 03:43
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iq...
10-07 06:02
Eisai And Biogen Announce Lecanemab-Irmb Subcutaneous Injection Is Now Available In US As Maintenance Dosing Regimen For AD Treatment
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection
10-07 04:34
Eisai And Biogen's LEQEMBI Approved By Australia's TGA For Early Alzheimer's In ApoEε4 Non-Carriers And Heterozygotes
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"))) announced today that the
09-24 19:34
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab...
09-24 14:56
派息除权日
|
每股总股息
| 派息日期 |
2025-12-30
|
0.40
|
2026-01-16
|
2025-11-03
|
0.40
|
2025-11-14
|
2025-08-29
|
0.40
|
2025-09-12
|
2025-05-30
|
0.40
|
2025-06-13
|
2024-12-30
|
0.50
|
2025-01-17
|
2024-11-04
|
0.40
|
2024-11-15
|
2024-08-26
|
0.40
|
2024-09-13
|
2024-05-31
|
0.39
|
2024-06-14
|
2023-12-28
|
0.38
|
2024-01-19
|
2023-11-03
|
0.37
|
2023-11-17
|
2023-08-25
|
0.35
|
2023-09-08
|
2023-05-30
|
0.32
|
2023-06-09
|
2022-12-29
|
0.28
|
2023-01-20
|
2022-11-04
|
0.18
|
2022-11-18
|
2022-08-26
|
0.24
|
2022-09-09
|
2022-05-27
|
0.24
|
2022-06-10
|
2021-12-29
|
0.24
|
2022-01-14
|
2021-11-05
|
0.24
|
2021-11-19
|
2021-07-30
|
0.24
|
2021-08-13
|
2021-04-30
|
0.24
|
2021-05-14
|
2020-12-30
|
0.24
|
2021-01-15
|
2020-10-30
|
0.24
|
2020-11-13
|
2020-07-31
|
0.24
|
2020-08-14
|
2020-05-01
|
0.24
|
2020-05-15
|
2019-12-30
|
0.30
|
2020-01-17
|
2019-11-01
|
0.30
|
2019-11-15
|
2019-08-02
|
0.30
|
2019-08-16
|
2019-05-03
|
0.30
|
2019-05-17
|
2018-12-28
|
0.30
|
2019-01-11
|
2018-10-26
|
0.30
|
2018-11-09
|
2018-08-03
|
0.30
|
2018-08-17
|
2018-05-04
|
0.30
|
2018-05-18
|
2017-12-28
|
0.30
|
2018-01-12
|
2017-10-27
|
0.30
|
2017-11-10
|
2017-07-28
|
0.30
|
2017-08-11
|
2017-05-02
|
0.30
|
2017-05-12
|
2016-12-28
|
0.30
|
2017-01-13
|
2016-11-03
|
0.30
|
2016-11-18
|
2016-07-28
|
0.30
|
2016-08-12
|
2016-04-28
|
0.30
|
2016-05-13
|
2015-12-29
|
0.30
|
2016-01-15
|
2015-11-02
|
0.30
|
2015-11-13
|
2015-07-30
|
0.30
|
2015-08-14
|
2015-04-29
|
0.30
|
2015-05-15
|
2014-12-29
|
0.30
|
2015-01-16
|
2014-10-30
|
0.30
|
2014-11-14
|
2014-07-30
|
0.30
|
2014-08-15
|
2014-04-24
|
0.30
|
2014-05-09
|
2013-12-27
|
0.30
|
2014-01-17
|
2013-10-24
|
0.30
|
2013-11-08
|
2013-08-01
|
0.30
|
2013-08-16
|
2013-04-25
|
0.30
|
2013-05-10
|
2012-12-27
|
0.40
|
2013-01-11
|
2012-10-25
|
0.30
|
2012-11-09
|
2012-07-26
|
0.30
|
2012-08-10
|
2012-05-03
|
0.30
|
2012-05-18
|
2011-12-28
|
0.45
|
2012-01-13
|
2011-10-27
|
0.30
|
2011-11-10
|
2011-07-28
|
0.30
|
2011-08-12
|
2011-04-20
|
0.30
|
2011-05-06
|
2010-12-29
|
0.54
|
2011-01-14
|
2010-10-28
|
0.54
|
2010-11-12
|
2010-07-29
|
0.54
|
2010-08-13
|
2010-04-22
|
0.54
|
2010-05-07
|
2009-12-29
|
0.54
|
2010-01-15
|
2009-10-22
|
0.54
|
2009-11-13
|
2009-07-30
|
0.54
|
2009-08-14
|
2009-04-30
|
0.54
|
2009-05-18
|
2008-12-29
|
0.54
|
2009-01-16
|
2008-10-29
|
0.54
|
2008-11-14
|
2008-07-30
|
0.54
|
2008-08-15
|
2008-05-01
|
0.54
|
2008-05-16
|
2007-12-27
|
0.97
|
2008-01-11
|
2007-10-25
|
0.54
|
2007-11-16
|
2007-07-25
|
0.54
|
2007-08-10
|
2007-05-03
|
0.52
|
2007-05-18
|
2006-12-27
|
1.00
|
2007-01-12
|
2006-10-26
|
0.50
|
2006-11-14
|
2006-07-26
|
0.50
|
2006-08-14
|
2006-04-28
|
0.48
|
2006-05-15
|
2005-12-28
|
0.91
|
2006-01-13
|
2005-10-27
|
0.46
|
2005-11-14
|
2005-07-27
|
0.46
|
2005-08-12
|
2005-04-28
|
0.46
|
2005-05-16
|
2004-12-29
|
0.74
|
2005-01-14
|
2004-10-28
|
0.46
|
2004-11-15
|
2004-07-28
|
0.55
|
2004-08-13
|
2004-05-05
|
0.41
|
2004-05-17
|
2003-12-29
|
0.76
|
2004-01-14
|
2003-10-29
|
0.36
|
2003-11-14
|
2003-07-29
|
0.36
|
2003-08-14
|
2003-04-30
|
0.36
|
2003-05-15
|
2002-12-27
|
0.36
|
2003-01-14
|
2002-10-29
|
0.36
|
2002-11-14
|
2002-07-30
|
0.43
|
2002-08-14
|
2002-05-01
|
0.47
|
2002-05-15
|
2001-12-27
|
0.47
|
2002-01-14
|
2001-10-29
|
0.47
|
2001-11-14
|
2001-08-01
|
0.47
|
2001-08-14
|
2001-05-04
|
0.47
|
2001-05-15
|
2000-12-27
|
1.37
|
2001-01-19
|
2000-10-27
|
0.47
|
2000-11-14
|
2000-07-27
|
0.47
|
2000-08-14
|
2000-05-04
|
0.45
|
2000-05-15
|
1999-12-29
|
1.46
|
2000-01-19
|
1999-10-27
|
0.43
|
1999-11-12
|
1999-07-28
|
0.43
|
1999-08-13
|
1999-05-03
|
0.41
|
1999-05-14
|
1998-12-29
|
0.71
|
1999-01-15
|
1998-10-28
|
0.40
|
1998-11-12
|
1998-07-29
|
0.40
|
1998-08-14
|
1998-05-04
|
0.40
|
1998-05-15
|
1997-12-29
|
1.70
|
1998-01-22
|
1997-10-29
|
0.75
|
1997-11-14
|
1997-07-29
|
0.73
|
1997-08-14
|
1997-05-01
|
0.71
|
1997-05-14
|
1996-12-27
|
0.70
|
1997-01-16
|
1996-10-29
|
0.70
|
1996-11-14
|
1996-07-29
|
0.70
|
1996-08-08
|
1996-04-26
|
0.70
|
1996-05-15
|
1995-12-27
|
1.62
|
1996-01-18
|
1995-10-27
|
0.70
|
1995-11-09
|
1995-07-27
|
0.70
|
1995-08-10
|
1995-04-25
|
0.70
|
1995-05-11
|
1994-12-23
|
0.22
|
1995-01-19
|
1994-11-01
|
0.70
|
1994-11-14
|
1994-07-27
|
0.70
|
1994-08-11
|
1994-04-26
|
0.70
|
1994-05-12
|
1993-12-27
|
0.70
|
1994-01-13
|
1993-10-27
|
0.70
|
1993-11-12
|
1993-07-28
|
0.70
|
1993-08-12
|
1993-04-27
|
0.70
|
1993-05-13
|
1992-12-24
|
0.70
|
1993-01-14
|
1992-10-26
|
0.70
|
1992-11-13
|
1992-07-28
|
0.70
|
1992-08-13
|
1992-04-24
|
0.70
|
1992-05-14
|
1991-12-24
|
0.70
|
1992-01-16
|
1991-10-25
|
0.70
|
1991-11-14
|
1991-07-25
|
0.70
|
1991-08-15
|
1991-04-24
|
0.70
|
1991-05-16
|
1990-12-24
|
0.70
|
1991-01-17
|
1990-10-25
|
0.70
|
1990-11-15
|
1990-07-25
|
0.70
|
1990-08-16
|
1990-04-24
|
0.70
|
1990-05-17
|
1989-12-22
|
0.70
|
1990-01-18
|
1989-10-27
|
0.70
|
1989-11-16
|
1989-07-25
|
0.95
|
1989-08-17
|
1989-04-26
|
0.95
|
1989-05-18
|
1988-12-23
|
0.95
|
1989-01-19
|
1988-10-25
|
0.95
|
1988-11-17
|
1988-07-25
|
0.95
|
1988-08-18
|
1988-04-25
|
0.95
|
1988-05-12
|
1987-12-24
|
0.95
|
1988-01-21
|
1987-10-26
|
0.95
|
1987-11-12
|
1987-07-27
|
0.90
|
1987-08-13
|
1987-04-24
|
0.90
|
1987-05-14
|
1987-01-26
|
0.90
|
1987-02-12
|
1986-10-27
|
0.90
|
1986-11-13
|
1986-07-25
|
0.85
|
1986-08-14
|
1986-04-24
|
0.80
|
1986-05-15
|
1984-07-25
|
0.70
|
1984-08-16
|
1984-04-24
|
0.66
|
1984-05-17
|
1984-01-25
|
0.65
|
1984-02-16
|
1983-10-25
|
0.64
|
1983-11-17
|
1983-07-25
|
0.64
|
1983-08-18
|
1983-04-25
|
0.64
|
1983-05-12
|
1983-01-25
|
0.64
|
1983-02-17
|
1982-10-25
|
0.64
|
1982-11-18
|
1982-07-26
|
0.64
|
1982-08-12
|
1982-04-26
|
0.64
|
1982-05-13
|
1982-01-25
|
0.64
|
1982-02-18
|
1981-10-26
|
0.64
|
1981-11-12
|
1981-07-27
|
0.62
|
1981-08-13
|
1981-04-24
|
0.50
|
1981-05-14
|
1981-01-26
|
0.46
|
1981-02-12
|
1980-10-27
|
0.46
|
1980-11-13
|
1980-07-25
|
0.45
|
1980-08-14
|
1980-04-23
|
0.45
|
1980-05-15
|
1980-01-24
|
0.43
|
1980-02-13
|
1979-10-24
|
0.43
|
1979-11-14
|
1979-07-24
|
0.43
|
1979-08-15
|
1979-04-23
|
0.42
|
1979-05-16
|
1979-01-24
|
0.42
|
1979-02-14
|
1978-10-24
|
0.42
|
1978-11-15
|
1978-07-24
|
0.41
|
1978-08-09
|
1978-04-24
|
0.41
|
1978-05-10
|
1978-01-29
|
0.40
|
1978-02-15
|
1977-10-24
|
0.38
|
1977-11-09
|
1977-07-24
|
0.38
|
1977-08-10
|
1977-04-24
|
0.38
|
1977-05-11
|
1977-01-24
|
0.40
|
1977-02-16
|
